$CCXI ChemoCentryx, Inc. Insider Trading

FREE EMAIL WATCHDOG

Get free email notifications about insider trading in ChemoCentryx, Inc..

  • Your email is safe with us.
  • The service is free and you can unsubscribe at any time.

General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview


Overview of insider trading in ChemoCentryx, Inc.. Insider overview, share value development, latest insider transactions and email notifications about new events in ChemoCentryx, Inc. for free.

CIK Number: 0001340652
IRS Number: 943254365
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Trading Symbol: CCXI
Company Address: 850 MAUDE AVENUE MOUNTAIN VIEW 94043

ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.

Market Capitalization: $309.30M
Prev close: $6.67
Average Daily Volume: 248,834
Days Low: $6.45
Year Low: $1.92
Year High: $9.10

ChemoCentryx, Inc. Insiders Active In Last 3 Months

NamePositionTotal SharesCurrent Value ($)Last 3 MonthsBuy / SellLast Transaction
Cappel Markus J.Chief Bus. Officer & Treasurer80,559537,329shares bought: 957,536 / shares sold: -923,386 BUYMay 12 202014 days ago
Jain RitaDirector12,97586,543shares bought: 12,975 / shares sold: 0 STRONG BUYMar 31 20202 months ago
KANAYA SUSAN MEVP, CFO and Sec.146,194975,114shares bought: 1,189,986 / shares sold: -958,813 BUYMay 06 202020 days ago
Kwan Pui SanPrincipal Acctg Officer4933,288shares bought: 213,091 / shares sold: -232,032 SELLMar 31 20202 months ago
Parker Geoffrey M.Director76,401509,595shares bought: 143,490 / shares sold: -42,815 STRONG BUYMar 25 20202 months ago
Schall Thomas J.President and CEO2,272,75815,159,296shares bought: 1,488,579 / shares sold: -1,473,201 BUYMay 12 202014 days ago

View all ChemoCentryx, Inc. insiders.

ChemoCentryx, Inc. Latest Insider Transactions

DateTickerCompanyOwnerRelationship Transaction Code Cost ($) Shares Transaction Value ($) Total Shares % Holdings
May 12 2020CCXIChemoCentryx, Inc.Schall Thomas J.President and CEOOption ExerciseM14.3135,865513,228126,513
May 12 2020CCXIChemoCentryx, Inc.Schall Thomas J.President and CEOOption ExerciseM14.3170,6081,010,400162,378
May 12 2020CCXIChemoCentryx, Inc.Schall Thomas J.President and CEOOption ExerciseM14.314,20160,116232,986
May 12 2020CCXIChemoCentryx, Inc.Schall Thomas J.President and CEOSellS57.7535,8652,071,1002,268,5572.3 M to 2.3 M (-1.56 %)
May 12 2020CCXIChemoCentryx, Inc.Schall Thomas J.President and CEOBuyM14.3135,865513,2282,304,4222.3 M to 2.3 M (+1.58 %)
May 12 2020CCXIChemoCentryx, Inc.Schall Thomas J.President and CEOSellS56.1416,029899,8742,268,5572.3 M to 2.3 M (-0.70 %)
May 12 2020CCXIChemoCentryx, Inc.Schall Thomas J.President and CEOSellS55.3354,5793,019,8562,284,5862.3 M to 2.3 M (-2.33 %)
May 12 2020CCXIChemoCentryx, Inc.Schall Thomas J.President and CEOBuyM14.3170,6081,010,4002,339,1652.3 M to 2.3 M (+3.11 %)
May 12 2020CCXIChemoCentryx, Inc.Schall Thomas J.President and CEOSellS55.014,201231,1152,268,5572.3 M to 2.3 M (-0.18 %)
May 12 2020CCXIChemoCentryx, Inc.Schall Thomas J.President and CEOBuyM14.314,20160,1162,272,7582.3 M to 2.3 M (+0.19 %)
May 12 2020CCXIChemoCentryx, Inc.Cappel Markus J.Chief Bus. Officer ...Option ExerciseM3.5734,222122,1735,606
May 12 2020CCXIChemoCentryx, Inc.Cappel Markus J.Chief Bus. Officer ...Option ExerciseM3.574,31215,39439,828
May 12 2020CCXIChemoCentryx, Inc.Cappel Markus J.Chief Bus. Officer ...SellS55.1134,2221,886,13576,247110.5 K to 76.2 K (-30.98 %)
May 12 2020CCXIChemoCentryx, Inc.Cappel Markus J.Chief Bus. Officer ...BuyM3.5734,222122,173110,46976.2 K to 110.5 K (+44.88 %)
May 12 2020CCXIChemoCentryx, Inc.Cappel Markus J.Chief Bus. Officer ...SellS50.014,312215,63976,24780.6 K to 76.2 K (-5.35 %)

View all ChemoCentryx, Inc. insider transactions.